LIlly comes on board at think tank

Share this article:
Eli Lilly
Eli Lilly

National Pharmaceutical Council (NPC) said Eli Lilly joined earlier this year. NPC conducts research on topics like the challenges of individual patient treatment effects, utilization of real-world evidence and comparative effectiveness research.

In a statement, Mark Nagy, Lilly VP, global patient outcomes and real world evidence, said, “With the full implementation of the Affordable Care Act, access to healthcare and medicines is becoming a reality for more Americans, while at the same time the personalization of drug treatments is beginning to become a reality. These changes are sparking new conversations and challenges, and I look forward to working with NPC to address them.”

Nagy will serve as Lilly's representative on the NPC board of directors.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions